Novocure (NVCR) Misses Q1 EPS by 9c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. GOOGL
9. RTX
10. S

Go back to Novocure (NVCR) Misses Q1 EPS by 9c

Novocure Reports First Quarter 2016 Financial Results and Provides Company Update

May 9, 2016 4:00 PM EDT

Increasing adoption of Optune with 755 prescriptions received in the first quarter 2016, an increase of 73 percent from the first quarter 2015 and 36 percent from the fourth quarter 2015

797 active patients at March 31, 2016, an increase of 114 percent from March 31, 2015 and 32 percent from December 31, 2015

First quarter 2016 reported revenues of $13.1 million, reflecting 151 percent growth versus first quarter 2015

More than 112 million Americans have coverage of Optune as a treatment for newly diagnosed and/or recurrent glioblastoma

Phase 2 pilot PANOVA results presented at ASCO GI suggest Tumor Treating Fields plus chemotherapy may be safe as first-line treatment and improve survival of patients... More